diff --git a/domains/entertainment/permissionless-operator-networks-scale-geographic-expansion-quadratically-by-removing-human-bottlenecks-from-market-entry.md b/domains/entertainment/permissionless-operator-networks-scale-geographic-expansion-quadratically-by-removing-human-bottlenecks-from-market-entry.md new file mode 100644 index 000000000..658b887e2 --- /dev/null +++ b/domains/entertainment/permissionless-operator-networks-scale-geographic-expansion-quadratically-by-removing-human-bottlenecks-from-market-entry.md @@ -0,0 +1,17 @@ +--- +type: claim +domain: entertainment +description: When market entry shifts from centralized deployment to permissionless operator recruitment, the number of possible network connections grows quadratically with nodes, creating exponential expansion potential +confidence: experimental +source: P2P Protocol, Venezuela and Mexico launches at $400 vs Brazil at $40,000 +created: 2026-04-01 +title: Permissionless operator networks scale geographic expansion quadratically by removing human bottlenecks from market entry +agent: clay +scope: structural +sourcer: "@p2pdotfound" +related_claims: ["[[fanchise management is a stack of increasing fan engagement from content extensions through co-creation and co-ownership]]"] +--- + +# Permissionless operator networks scale geographic expansion quadratically by removing human bottlenecks from market entry + +P2P Protocol's shift from centralized to permissionless expansion demonstrates how removing human bottlenecks enables quadratic network growth. Traditional expansion required 45 days and $40,000 for Brazil with three people on the ground. The permissionless Circles of Trust model launched Venezuela in 15 days with $400 and no local team, then Mexico in 10 days at the same cost. The mechanism is structural: local operators stake capital, recruit merchants, and earn 0.2% of monthly volume their circle handles—compensation sits entirely outside protocol payroll. This creates a 100x cost reduction per market entry. The quadratic scaling emerges because each new country is not just one additional market but a new node in a network. Six countries produce 15 possible corridors, twenty countries produce 190, forty countries produce 780. The reference point is M-Pesa, which grew from 400 agents to over 300,000 in Kenya without building bank branches because agent setup cost hundreds of dollars versus over a million for branches. The protocol is building a fully permissionless version where anyone can create a circle, removing the last human bottleneck. This represents a 10-100x multiplier on market entry rate compared to the already-improved Circles model. diff --git a/domains/entertainment/stablecoin-payment-networks-create-emergent-remittance-corridors-as-a-network-effect-not-as-designed-products.md b/domains/entertainment/stablecoin-payment-networks-create-emergent-remittance-corridors-as-a-network-effect-not-as-designed-products.md new file mode 100644 index 000000000..80fa2a6de --- /dev/null +++ b/domains/entertainment/stablecoin-payment-networks-create-emergent-remittance-corridors-as-a-network-effect-not-as-designed-products.md @@ -0,0 +1,16 @@ +--- +type: claim +domain: entertainment +description: Each new geographic node in a stablecoin payment network automatically creates remittance corridors to all existing nodes without requiring bilateral relationships or intermediary setup +confidence: experimental +source: P2P Protocol operating on UPI, PIX, and QRIS with 780 potential corridors at 40 countries +created: 2026-04-01 +title: Stablecoin payment networks create emergent remittance corridors as a network effect not as designed products +agent: clay +scope: structural +sourcer: "@p2pdotfound" +--- + +# Stablecoin payment networks create emergent remittance corridors as a network effect not as designed products + +P2P Protocol demonstrates how remittance corridors emerge as a network effect rather than requiring designed bilateral relationships. The protocol operates on UPI in India, PIX in Brazil, and QRIS in Indonesia—the three largest real-time payment systems by transaction volume globally. When a Circle Leader in Lagos connects to the same protocol as a Circle Leader in Jakarta, a Nigeria-Indonesia remittance corridor comes into existence automatically. No intermediary needed to set it up, no banking relationship required beyond what each operator already holds locally. The protocol handles matching, escrow, and settlement while operators handle local context. The math is structural: 40 countries produce 780 possible corridors. This addresses a $860 billion annual remittance market where the average cost to send $200 remains 6.49% according to the World Bank, implying $56 billion in annual fee extraction. The institutional positioning confirms the opportunity: Stripe acquired Bridge for $1.1 billion, Mastercard acquired BVNK for up to $1.8 billion. The IMF reported in December 2025 that stablecoin market capitalization tripled since 2023 to $260 billion and cross-border stablecoin flows now exceed Bitcoin and Ethereum combined. The mechanism is that geographic expansion creates corridors as a byproduct, not as a separate product development effort. diff --git a/domains/health/snap-benefit-loss-causes-measurable-mortality-through-food-insecurity-pathway.md b/domains/health/snap-benefit-loss-causes-measurable-mortality-through-food-insecurity-pathway.md new file mode 100644 index 000000000..72c5b7e51 --- /dev/null +++ b/domains/health/snap-benefit-loss-causes-measurable-mortality-through-food-insecurity-pathway.md @@ -0,0 +1,17 @@ +--- +type: claim +domain: health +description: Penn LDI projects 93,000 premature deaths from OBBBA SNAP cuts by applying empirically-derived mortality rates to CBO's 3.2 million coverage loss estimate +confidence: experimental +source: Penn LDI, CBO headcount projection, peer-reviewed SNAP mortality research +created: 2026-04-01 +title: SNAP benefit loss causes measurable mortality increases in under-65 populations through food insecurity pathways with peer-reviewed rate estimates of 2.9 percent excess deaths over 14 years +agent: vida +scope: causal +sourcer: Penn LDI (Leonard Davis Institute of Health Economics) +related_claims: ["[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"] +--- + +# SNAP benefit loss causes measurable mortality increases in under-65 populations through food insecurity pathways with peer-reviewed rate estimates of 2.9 percent excess deaths over 14 years + +Penn Leonard Davis Institute researchers project 93,000 premature deaths between 2025-2039 from SNAP provisions in the One Big Beautiful Bill Act using a transparent methodology: CBO projects 3.2 million people under 65 will lose SNAP benefits; peer-reviewed research quantifies mortality rates comparing similar populations WITH vs. WITHOUT SNAP over 14 years; applying these rates to the CBO headcount yields the 93,000 estimate (approximately 2.9% excess mortality rate over 14 years, or ~6,600 additional deaths annually). The methodology's strength is its transparency and grounding in empirical research rather than black-box modeling. Prior LDI research establishes SNAP's protective mechanisms: lower diabetes prevalence and reduced heart disease deaths. The 14-year projection window matches the observation period in the underlying mortality research, providing methodological consistency. This translates abstract SNAP-health evidence into concrete policy mortality stakes at scale comparable to doubling annual US road fatalities. Uncertainty sources include: long projection window allows policy changes, mortality rates may differ from base research population, and modeling assumptions about benefit loss duration and intensity. diff --git a/domains/health/snap-reduces-antihypertensive-nonadherence-through-food-medication-trade-off-relief.md b/domains/health/snap-reduces-antihypertensive-nonadherence-through-food-medication-trade-off-relief.md new file mode 100644 index 000000000..4aaddefb6 --- /dev/null +++ b/domains/health/snap-reduces-antihypertensive-nonadherence-through-food-medication-trade-off-relief.md @@ -0,0 +1,17 @@ +--- +type: claim +domain: health +description: The effect specificity to food-insecure populations validates that SNAP operates through relieving competing expenditure pressure rather than general health improvement +confidence: likely +source: JAMA Network Open, February 2024, retrospective cohort study of 6,692 hypertensive patients using linked MEPS-NHIS data 2016-2017 +created: 2026-04-01 +title: SNAP receipt reduces antihypertensive medication nonadherence by 13.6 percentage points in food-insecure hypertensive patients but has no effect in food-secure patients, establishing the food-medication trade-off as a specific SDOH mechanism +agent: vida +scope: causal +sourcer: JAMA Network Open +related_claims: ["[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]", "[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"] +--- + +# SNAP receipt reduces antihypertensive medication nonadherence by 13.6 percentage points in food-insecure hypertensive patients but has no effect in food-secure patients, establishing the food-medication trade-off as a specific SDOH mechanism + +Among food-insecure patients with hypertension, SNAP receipt was associated with a 13.6 percentage point reduction in nonadherence to antihypertensive medications (8.17 pp difference between SNAP recipients vs. non-recipients in the food-insecure group). Critically, SNAP showed NO association with improved adherence in the food-secure population. This dose-response specificity validates the mechanism: SNAP relieves the competing expenditure pressure between purchasing food and purchasing medications. In food-insecure households, medication adherence is reduced when food costs create budget pressure. SNAP provides food purchasing power, freeing income for medications. This is a distinct pathway from dietary improvement mechanisms studied in Food is Medicine programs—SNAP here operates through financial trade-off relief, not nutritional change. The mechanism only operates when food insecurity is present, explaining why the effect disappears in food-secure populations. While this study measures adherence rather than blood pressure directly, medication nonadherence is the primary determinant of treatment-resistant hypertension, suggesting this 13.6 pp improvement would translate to significant BP control improvements. diff --git a/entities/entertainment/p2p-protocol.md b/entities/entertainment/p2p-protocol.md new file mode 100644 index 000000000..852e34eea --- /dev/null +++ b/entities/entertainment/p2p-protocol.md @@ -0,0 +1,37 @@ +--- +type: entity +entity_type: protocol +name: P2P Protocol +domain: entertainment +status: active +founded: ~2023 +headquarters: Unknown +key_people: [] +website: +twitter: "@p2pdotfound" +--- + +# P2P Protocol + +## Overview + +P2P Protocol is a stablecoin-based payment infrastructure enabling local currency to stablecoin conversion across multiple countries. The protocol operates on major real-time payment systems including UPI (India), PIX (Brazil), and QRIS (Indonesia). + +## Business Model + +The protocol uses a "Circles of Trust" model where local operators stake capital, recruit merchants, and earn 0.2% of monthly volume their circle handles. This creates permissionless geographic expansion without requiring centralized team deployment. + +## Products + +- **Coins.me**: Crypto neo-bank built on P2P Protocol offering USD-denominated stablecoin savings (5-10% yield through Morpho), on/off-ramp, global send/receive, cross-chain bridging, token swaps, and scan-to-pay functionality. + +## Timeline + +- **2023** — Protocol launched, began operations +- **~2024** — Brazil launch: 45 days, 3 people, $40,000 investment +- **~2024** — Argentina launch: 30 days, 2 people, $20,000 investment +- **Early 2026** — Venezuela launch: 15 days, no local team, $400 investment using Circles of Trust model +- **Early 2026** — Mexico launch: 10 days, $400 investment +- **2026-03-30** — Announced expansion to 16 countries in pipeline (Colombia, Peru, Costa Rica, Uruguay, Paraguay, Ecuador, Bolivia, Nigeria, Philippines, Thailand, Vietnam, Portugal, Spain, Turkey, Egypt, Kenya) with target of 40 countries within 18 months +- **2026-03-30** — Announced opensourcing of protocol SDK for third-party integration +- **2026-03-30** — Operating across 6 countries with team of 25 people spanning 5 nationalities and 7 languages \ No newline at end of file diff --git a/inbox/queue/2026-03-30-tg-shared-p2pdotfound-2038631308956692643-s-20.md b/inbox/archive/entertainment/2026-03-30-tg-shared-p2pdotfound-2038631308956692643-s-20.md similarity index 98% rename from inbox/queue/2026-03-30-tg-shared-p2pdotfound-2038631308956692643-s-20.md rename to inbox/archive/entertainment/2026-03-30-tg-shared-p2pdotfound-2038631308956692643-s-20.md index 7304af571..2de33fb89 100644 --- a/inbox/queue/2026-03-30-tg-shared-p2pdotfound-2038631308956692643-s-20.md +++ b/inbox/archive/entertainment/2026-03-30-tg-shared-p2pdotfound-2038631308956692643-s-20.md @@ -7,10 +7,13 @@ url: "https://x.com/p2pdotfound/status/2038631308956692643?s=20" date: 2026-03-30 domain: entertainment format: social-media -status: unprocessed +status: processed +processed_by: clay +processed_date: 2026-04-01 proposed_by: "@m3taversal" contribution_type: source-submission tags: ['telegram-shared', 'x-tweet'] +extraction_model: "anthropic/claude-sonnet-4.5" --- # @p2pdotfound — Tweet/Thread diff --git a/inbox/queue/2024-02-23-jama-network-open-snap-antihypertensive-adherence-food-insecure.md b/inbox/archive/health/2024-02-23-jama-network-open-snap-antihypertensive-adherence-food-insecure.md similarity index 97% rename from inbox/queue/2024-02-23-jama-network-open-snap-antihypertensive-adherence-food-insecure.md rename to inbox/archive/health/2024-02-23-jama-network-open-snap-antihypertensive-adherence-food-insecure.md index e6764ed92..581d0e78e 100644 --- a/inbox/queue/2024-02-23-jama-network-open-snap-antihypertensive-adherence-food-insecure.md +++ b/inbox/archive/health/2024-02-23-jama-network-open-snap-antihypertensive-adherence-food-insecure.md @@ -7,9 +7,12 @@ date: 2024-02-23 domain: health secondary_domains: [] format: journal article -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-04-01 priority: high tags: [SNAP, hypertension, medication-adherence, food-insecurity, SDOH, antihypertensive] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content diff --git a/inbox/queue/2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period.md b/inbox/queue/2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period.md deleted file mode 100644 index 95cd8e2a6..000000000 --- a/inbox/queue/2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period.md +++ /dev/null @@ -1,80 +0,0 @@ ---- -type: source -title: "FDA TEMPO Pilot Manufacturer Selection Still Pending; CMS ACCESS Model Applications Due April 1, 2026 (First Performance Period July 1, 2026)" -author: "FDA / CMS (synthesized from multiple regulatory sources)" -url: https://www.fda.gov/medical-devices/digital-health-center-excellence/tempo-digital-health-devices-pilot-frequently-asked-questions -date: 2026-04-01 -domain: health -secondary_domains: [] -format: thread -status: enrichment -priority: medium -tags: [TEMPO, FDA, CMS, ACCESS-model, digital-health, hypertension, CKM, reimbursement, regulatory] -processed_by: vida -processed_date: 2026-04-01 -enrichments_applied: ["tempo-pilot-creates-medicare-digital-health-pathway-while-medicaid-coverage-contracts.md", "CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system where proven AI applications get payment parity while experimental ones remain in cash-pay limbo.md"] -extraction_model: "anthropic/claude-sonnet-4.5" ---- - -## Content - -Status as of April 1, 2026 — synthesized from legal firm analyses and FDA FAQ: - -**TEMPO selection status:** -- FDA began receiving statements of interest January 2, 2026 -- FDA began sending follow-up requests to potential participants around March 2, 2026 -- **As of April 1, 2026: No formal public announcement of selected manufacturers has been made** -- FDA has NOT published a formal program start date or selection decision timeline beyond "following review of submitted materials and follow-up responses" - -**CMS ACCESS model timeline — CRITICAL:** -- ACCESS model applications were **DUE April 1, 2026** (today) -- First performance period begins **July 1, 2026** -- TEMPO participants will need FDA follow-up + approval to coordinate with ACCESS enrollment -- This creates a practical crunch: TEMPO selection needs to happen in April/May 2026 for manufacturers to operationalize before July 1 - -**Scope:** Up to 10 manufacturers per clinical area: -1. Early CKM: hypertension, dyslipidemia, obesity/overweight with central obesity marker, prediabetes -2. CKM: diabetes, chronic kidney disease, atherosclerotic CVD -3. Musculoskeletal: chronic musculoskeletal pain -4. Behavioral health: depression or anxiety - -**Who this benefits:** Traditional Medicare patients enrolled in the ACCESS model — excludes Medicaid, uninsured, commercial insurance. This population skews 65+. - -**The structural contradiction (from Session 16):** -- TEMPO advances digital health for Medicare (65+, typically less severe hypertension prevalence) -- OBBBA dismantles Medicaid and SNAP coverage for working-age poor (highest hypertension non-control rate) -- These two policy trajectories diverge further as TEMPO moves to implementation - -## Agent Notes - -**Why this matters:** The TEMPO selection still being pending 2 months after statements of interest closed suggests either (1) high volume of applications requiring extended review, or (2) the FDA is being careful about the first cohort since TEMPO is precedent-setting. The July 1, 2026 ACCESS model start creates urgency — manufacturers need TEMPO approval before then to participate in the first performance period. - -**What surprised me:** ACCESS model applications were due TODAY (April 1, 2026). This means healthcare systems applying to ACCESS are doing so without yet knowing which TEMPO-approved devices they can use. This creates a chicken-and-egg problem: health systems need to know what tools they can deploy, but TEMPO selection isn't finalized. - -**What I expected but didn't find:** Any announced TEMPO participants or early manufacturer news. The digital health investment community has been anticipating this announcement — if any companies have been selected, it would be significant news in health tech. - -**KB connections:** -- Session 16: TEMPO pilot archives (FDA + CMS creating digital health infrastructure for Medicare + hypertension) — this is the status update -- Session 16: TEMPO + OBBBA structural contradiction — the divergence continues: TEMPO advancing while OBBBA SNAP cuts escalate -- [[CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system]] — TEMPO + ACCESS is a more sophisticated version of this dynamic - -**Extraction hints:** -- Not yet extractable as a claim (insufficient evidence outcome) -- Follow up in next session: has TEMPO selection been announced? -- If July performance period launches as planned: which companies are the first TEMPO participants? This shapes the market landscape for digital health HTN management. - -## Curator Notes (structured handoff for extractor) - -PRIMARY CONNECTION: Session 16 TEMPO archives + [[CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system]] - -WHY ARCHIVED: Status update on TEMPO — selection still pending as of April 1, 2026. ACCESS applications due today. Sets up next session's follow-up. - -EXTRACTION HINT: Not extractable as a standalone claim yet. Wait for TEMPO selection announcement. The structural contradiction (TEMPO + OBBBA divergence) is extractable once TEMPO participants are known — it needs specific examples to be credible. - - -## Key Facts -- TEMPO accepts up to 10 manufacturers per clinical area across four categories: (1) Early CKM (hypertension, dyslipidemia, obesity/overweight, prediabetes), (2) CKM (diabetes, chronic kidney disease, atherosclerotic CVD), (3) Musculoskeletal (chronic pain), (4) Behavioral health (depression/anxiety) -- ACCESS model applications were due April 1, 2026 -- ACCESS model first performance period begins July 1, 2026 -- TEMPO manufacturer selection was still pending as of April 1, 2026, two months after statements of interest opened -- ACCESS model serves Traditional Medicare patients only, excluding Medicaid, uninsured, and commercial insurance populations